Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: Curtis E. Bemis who wrote (189)	12/8/1999 5:59:00 PM
From: LLCF	Read Replies (1) \| Respond to of 395

<In the study 18 patients with autism and 10 with pervasive developmental disorder (PDD) were administered a single dose of secretin and evaluated for four weeks against a placebo group. While the authors acknowledge limitations related to the study's length, dosing and design, they conclude that secretin is not an effective treatment for autism.> How did they define 'autism'? Hell aren't there tons of different cancer therapies depending apon what's going on? Are these guys lame, or what?? Am I missing something? DAK